navicixizumab (OMP-305B83)

News alerts, weekly reports and conference planners

Company:

Feng Biosciences, Mereo Biopharma

Drug class:

VEGFR inhibitor, DLL4 inhibitor

Related drugs:

‹

›

No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	OMP-305B83 Sensitive: B - Late Trials OMP-305B83 Sensitive : B	OMP-305B83 Sensitive: B - Late Trials OMP-305B83 Sensitive : B
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	OMP-305B83 Sensitive: B - Late Trials OMP-305B83 Sensitive : B	OMP-305B83 Sensitive: B - Late Trials OMP-305B83 Sensitive : B
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	OMP-305B83 Sensitive: B - Late Trials OMP-305B83 Sensitive : B	OMP-305B83 Sensitive: B - Late Trials OMP-305B83 Sensitive : B

Associations
(3)